{"id":481465,"title":"Notice: Multiple additions to the Prescription Drug List (PDL) [2024-02-28] - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-06","captureTimestamp":"2026-01-06T16:45:12.776000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2024-02-28.html?wbdisable=true","snippet":"Notice: Multiple additions to the Prescription Drug List (PDL) [2024-02-28] February 28, 2024 Our file number: 24-101144 - 694 The purpose of this Notice of Amendment is to notify about the addition of elranatamab, epcoritamab, etranacogene dezaparvovec, fidanacogene elaparvovec,…","rawSnapshotUrl":"/api/snapshots/raw/481465","browseUrl":"https://replay.healtharchive.ca/job-6/20260106164512/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2024-02-28.html?wbdisable=true#ha_snapshot=481465","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}